Is slow-onset long-acting monoamine transport blockade to cocaine as methadone is to heroin implication for anti-addiction medications

Neuropsychopharmacology

Volumn 35, Issue 13, 2010, Pages 2564-2578

  Peng, Xiao Qing ^a   Xi, Zheng Xiong ^a   Li, Xia ^a   Spiller, Krista ^a   Li, Jie ^a   Chun, Lauren ^a   Wu, Kuo Ming ^b   Froimowitz, Mark ^b,c   Gardner, Eliot L ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b Pharm Eco Laboratories   (United States)

^c DNAPrint Genomics Inc   (United States)

Author keywords

31,345; addiction; cocaine; DA transporter; heroin; methadone

Indexed keywords

[4 (3,4 DICHLOROPHENYL) 1,2,3,4 TETRAHYDRONAPHTHALEN 1 YL]DIMETHYLAMMONIUM CHLORIDE; DOPAMINE; DRUGS USED IN THE TREATMENT OF ADDICTION; METHADONE; TETRALIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DEPTH STIMULATION; COCAINE DEPENDENCE; CONTROLLED STUDY; HEROIN DEPENDENCE; MALE; METHADONE TREATMENT; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT;

ANIMALS; BRAIN; COCAINE; COCAINE-RELATED DISORDERS; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; EXTINCTION, PSYCHOLOGICAL; HEROIN; MALE; METHADONE; NUCLEUS ACCUMBENS; PLASMA MEMBRANE NEUROTRANSMITTER TRANSPORT PROTEINS; RATS; RATS, LONG-EVANS; SELF ADMINISTRATION; TETRAHYDRONAPHTHALENES;

EID: 78149466670     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2010.133     Document Type: Article

References (65)

1. 2 antagonists. Behav Pharmacol 1: 355-363.
2. 2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism. Mol Pharmacol 71: 1222-1232.
3. Busto U, Sellers EM (1986). Pharmacokinetic determinants of drug abuse and dependence. A conceptual perspective. Clin Pharmacokinet 11: 144-153.
4. Carroll FI, Howard JL, Howell LL, Fox BS, Kuhar MJ (2006). Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse. AAPS J 8: E196-E203.
5. Chen N, Reith MEA (2007). Substrates and inhibitors display different sensitivity to expression level of the dopamine transporter in heterologously expressing cells. J Neurochem 101: 377-388.
6. Chen R, Tilley MR, Wei H, Zhou F, Zhou F-M, Ching S et al (2006). Abolished cocaine reward in mice with a cocaine-insensitive dopamine transporter. Proc Natl Acad Sci USA 103: 9333-9338.
7. Chi L, Reith MEA (2003). Substrate-induced trafficking of the dopamine transporter in heterologously expressing cells and in rat striatal synaptosomal preparations. J Pharmacol Exp Ther 307: 729-736.
8. Daglish MR, Williams TM, Wilson SJ, Taylor LG, Eap CB, Augsburger M et al (2008). Brain dopamine response in human opioid addiction. Br J Psychiatry 193: 65-72.
9. Daws LC, Callaghan PD, Morón JA, Kahlig KM, Shippenberg TS, Javitch JA et al (2002). Cocaine increases dopamine uptake and cell surface expression of dopamine transporters. Biochem Biophys Res Commun 290: 1545-1550.
10. Desai RI, Kopajtic TA, Koffarnus M, Newman AH, Katz JL (2005). Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine. J Neurosci 25: 1889-1893.
11. Di Chiara G (1995). The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend 38: 95-137.
12. Dole VP, Nyswander ME (1965). A medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride. JAMA 193: 646-650.
13. Dole VP, Nyswander ME, Kreek MJ (1966). Narcotic blockade. Arch Intern Med 118: 304-309.
14. Donny EC, Brasser SM, Bigelow GE, Stitzer ML, Walsh SL (2005). Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction 100: 1496-1509.
15. Donny EC, Walsh SL, Bigelow GE, Eissenberg T, Stitzer ML (2002). High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans. Psychopharmacology 161: 202-212.
16. Ferragud A, Velázquez-Sánchez C, Hernández-Rabaza V, Nácher A, Merino V, Cardá M et al (2009). A dopamine transport inhibitor with markedly low abuse liability suppresses cocaine self-administration in the rat. Psychopharmacology 207: 281-289.
17. Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL et al (2008). Treating Tabacco Use and DependenceFClinical Practice Guideline: 2008 Update (Agency for Health Care Research and Quality [AHRQ] Publication No. 08-0050-1). United States Department of Health and Human Services (U.S. Public Health Service): Rockville, Maryland.
18. Froimowitz M, Gu Y, Dakin LA, Nagafuji PM, Kelley CJ, Parrish D et al (2007). Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter. J Med Chem 50: 219-232.
19. Froimowitz M, Wu K-M, Moussa A, Haidar RM, Jurayj J, George C et al (2000). Slow-onset, long-duration 3-(3,4-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse. J Med Chem 43: 4981-4992.
20. Gardner EL (2000). What we have learned about addiction from animal models of drug self-administration. Am J Addict 9: 285-313.
21. Gardner EL, Liu X, Paredes W, Giordano A, Spector J, Lepore M et al (2006). A slow-onset, long-duration indanamine mono-amine reuptake inhibitor as a potential maintenance pharma-cotherapy for psychostimulant abuse: effects in laboratory rat models relating to addiction. Neuropharmacology 51: 993-1003.
22. Glowa JR, Fantegrossi WE, Lewis DB, Matecka D, Rice KC, Rothman RB (1996). Sustained decrease in cocaine-maintained responding in rhesus monkeys with 1-[2-[bis(4-fluorophenyl)-methoxy]ethyl]-4-(3-hydroxy-3-phenylpropyl) piperazinyl de-canoate, a long-acting ester derivative of GBR 12909. J Med Chem 39: 4689-4691.
23. Grabowski J, Shearer J, Merrill J, Negus SS (2004). Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict Behav 29: 1439-1464.
24. Howell LL, Wilcox KM (2001). The dopamine transporter and cocaine medication development: drug self-administration in nonhuman primates. J Pharmacol Exp Ther 298: 1-6.
25. Jones BE, Prada JA (1977). Effects of methadone and morphine maintenance on drug-seeking behavior in the dog. Psychophar-macology 54: 109-112.
26. Kahlig KM, Lute BJ, Wei Y, Loland CJ, Gether U, Javitch JA et al (2006). Regulation of dopamine transporter trafficking by intracellular amphetamine. Mol Pharmacol 70: 542-548.
27. Keith DE, Anton B, Murray SR, Zaki PA, Chu PC, Lissin DV et al (1998). m-Opioid receptor internalization: opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain. Mol Pharmacol 53: 377-384.
28. Koob GF, Ahmed SH, Boutrel B, Chen SA, Kenny PJ, Markou A et al (2004). Neurobiological mechanisms in the transition from drug use to drug dependence. Neurosci Biobehav Rev 27: 739-749.
29. 1 dopamine receptor antagonist SCH 23390 increases cocaine self-administration in the rat. Neurosci Lett 79: 315-320.
30. Kozlowski LT, Giovino GA, Edwards B, Difranza J, Foulds J, Hurt R et al (2007). Advice on using over-the-counter nicotine replacement therapy-patch, gum, or lozenge-to quit smoking. Addict Behav 32: 2140-2150.
31. Kramer HK, Simon EJ (1999). Role of protein kinase C (PKC) in agonist-induced m-opioid receptor down-regulation: I. PKC translocation to the membrane of SH-SY5Y neuroblastoma cells is induced by m-opioid agonists. J Neurochem 72: 585-593.
32. Kreek MJ (2000). Methadone-related opioid agonist pharmacother-apy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann NY Acad Sci 909: 186-216.
33. Kuhar MJ, Pilotte NS (1996). Neurochemical changes in cocaine withdrawal. Trends Pharmacol Sci 17: 260-264.
34. Lepore M, Franklin KBJ (1992). Modeling drug kinetics with brain stimulation: dopamine antagonists increase self-stimulation. Pharmacol Biochem Behav 41: 489-496.
35. Leri F, Tremblay A, Sorge RE, Stewart J (2004). Methadone maintenance reduces heroin-and cocaine-induced relapse without affecting stress-induced relapse in a rodent model of poly-drug use. Neuropsychopharmacology 29: 1312-1320.
36. LeSage MG, Stafford D, Glowa JR (1999). Preclinical research on cocaine self-administration: environmental determinants and their interaction with pharmacological treatment. Neurosci Biobehav Rev 23: 717-741.
37. Little KY, Elmer LW, Zhong H, Scheys JO, Zhang L (2002). Cocaine induction of dopamine transporter trafficking to the plasma membrane. Mol Pharmacol 61: 436-445.
38. Loder MK, Melikian HE (2003). The dopamine transporter constitutively internalizes and recycles in a protein kinase C-regulated manner in stably transfected PC12 cell lines. J Biol Chem 278: 22168-22174.
39. Loland CJ, Desai RI, Zou M-F, Cao J, Grundt P, Gerstbrein K et al (2008). Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors. Mol Pharmacol 73: 813-823.
40. Mayfield RD, Zahniser NR (2001). Dopamine D2 receptor regulation of the dopamine transporter expressed in Xenopus laevis oocytes is voltage-independent. Mol Pharmacol 59: 113-121.
41. Newman AH, Kulkarni S (2002). Probes for the dopamine transporter: new leads toward a cocaine-abuse therapeuticFA focus on analogues of benztropine and rimcazole. Med Res Rev 22: 429-464.
42. O'Brien CP (1997). A range of research-based pharmacotherapies for addiction. Science 278: 66-70.
43. Oldendorf WH (1992). Some relationships between addiction and drug delivery to the brain. NIDA Res Monogr 120: 13-25.
44. Patel MB, Patel CN, Rajashekara V, Yoburn BC (2002). Opioid agonists differentially regulate m-opioid receptors and trafficking proteins in vivo. Mol Pharmacol 62: 1464-1470.
45. Paxinos G, Watson C (1998). The Rat Brain in Stereotaxic Coordinates, 4th edn. Academic Press: Sydney.
46. Platt DM, Rowlett JK, Spealman RD (2002). Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development. Psychopharmacology 163: 265-282.
47. Reith MEA, Berfield JL, Wang LC, Ferrer JV, Javitch JA (2001). The uptake inhibitors cocaine and benztropine differentially alter the conformation of the human dopamine transporter. J Biol Chem 31: 29012-29018.
48. Rothman RB, Baumann MH, Prisinzano TE, Newman AH (2008). Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction. Biochem Pharmacol 75: 2-16.
49. Rothman RB, Glowa JR (1995). A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Focus on GBR 12909. Mol Neurobiol 11: 1-19.
50. Runyon SP, Carroll FI (2006). Dopamine transporter ligands: recent developments and therapeutic potential. Curr Top Med Chem 6: 1825-1843.
51. Saunders C, Ferrer JV, Shi L, Chen J, Merrill G, Lamb ME et al (2000). Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci USA 97: 6850-6855.
52. 3 receptor agonist BP-897 attenuate methamphetamine-en-hanced brain stimulation reward in rats. Psychopharmacology 196: 533-542.
53. Veilleux JC, Colvin PJ, Anderson J, York C, Heinz AJ (2010). A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev 30: 155-166.
54. Volkow ND, Ding Y-S, Fowler JS, Wang G-J, Logan J, Gatley JS et al (1995). Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 52: 456-463.
55. Welch WM, Kraska AR, Sarges R, Koe BK (1984). Nontricyclic antidepressant agents derived from cis-and trans-1-amino-4-aryltetralins. J Med Chem 27: 1508-1515.
56. Wise RA (1996). Neurobiology of addiction. Curr Opin Neurobiol 6: 243-251.
57. Wise RA, Gardner EL (2004). Animal models of addiction. In: Charney DS, Nestler EJ (eds). Neurobiology of Mental Illness, 2nd edn, Oxford University Press: London. pp 683-697.
58. Woolverton WL, Wang Z (2004). Relationship between injection duration, transporter occupancy and reinforcing strength of cocaine. Eur J Pharmacol 486: 251-257.
59. 3 receptor antagonism by SB-277011A attenuates cocaine reinforcement as assessed by progressive-ratio and variable-cost-variable-payoff fixed-ratio cocaine self-administration in rats. Eur J Neurosci 21: 3427-3438.
60. Xi Z-X, Li X, Peng X-Q, Li J, Chun L, Gardner EL et al (2010). Inhibition of NAALADase by 2-PMPA attenuates cocaine-induced relapse in rats: a NAAG-mGluR2/3-mediated mechanism. J Neurochem 112: 564-576.
61. 3 receptor antagonist NGB 2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats. Neuropsycho-pharmacology 31: 1393-1405.
62. Xi Z-X, Ramamoorthy S, Shen H, Lake R, Samuvel DJ, Kalivas PW (2003). GABA transmission in the nucleus accumbens is altered after withdrawal from repeated cocaine. J Neurosci 23: 3498-3505.
63. Xi Z-X, Stein EA (2002). GABAergic mechanisms of opiate reinforcement. Alcohol Alcohol 37: 485-494.
64. Zahniser NR, Sorkin A (2004). Rapid regulation of the dopamine transporter: role in stimulant addiction? Neuropharmacology 47(Suppl 1): 80-91.
65. Zapata A, Kivell B, Han Y, Javitch JA, Bolan EA, Kuraguntla D et al (2007). Regulation of dopamine transporter function and cell surface expression by D3 dopamine receptors. J Biol Chem 282: 35842-35854.